Using Immunotherapy Combinations in Hepatocellular Carcinoma

home / case-based-roundtable-series / using-immunotherapy-combinations-in-hepatocellular-carcinoma

This roundtable series reviews immunotherapy in patients with unresectable hepatocellular carcinoma as first-line treatment, as discussed by key opinion leaders and participants at virtual live events.

The Expansion of Treatment in the Firstline Setting of HCC

The Expansion of Treatment in the Firstline Setting of HCC

Richard D. Kim, MD
December 22nd 2022

Richard Kim, MD, walks through options in the frontline setting for patients with advanced staged hepatocellular carcinoma and how newer treatments have impacted this patient population.

Phase 3 HIMALAYA Trial Shows OS Benefit of Durvalumab in HCC

Phase 3 HIMALAYA Trial Shows OS Benefit of Durvalumab in HCC

Milind Javle, MD
January 18th 2023

Milind Javle, MD, discusses the phase 3 HIMALAYA study of durvalumab and tremelimumab in patients with locally advanced or metastatic hepatocellular cancer.

Comparing IMbrave150 and HIMALAYA Outcomes in Frontline HCC

Comparing IMbrave150 and HIMALAYA Outcomes in Frontline HCC

Targeted Oncology Staff
July 24th 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Renuka Iyer, MD, discussed the study designs, patient populations, and efficacy outcomes of the IMbrave150 and HIMALAYA trials of frontline immunotherapy-containing regimens for patients with hepatocellular carcinoma. This is the first of 2 articles based on this event.

Analyses Show Subgroup-Dependent Benefits of Immunotherapy in HCC

Analyses Show Subgroup-Dependent Benefits of Immunotherapy in HCC

Targeted Oncology Staff
August 1st 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Renuka Iyer, MD, discussed subgroup analyses of the HIMALAYA trial of frontline durvalumab plus tremelimumab for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.